Umang Vohra, the company’s managing director and global CEO, said Cipla does not expect potential tariffs on U.S. drug imports or potential tariffs on the U.S. president’s recent order to reduce prescription drugs to lower prescription drugs will not have an immediate impact.
“I think our business continues as usual, and there are no shutdowns anywhere in the U.S. due to any confusion in tariffs… so we don’t see the impact,” Vohra said, adding that the company is monitoring the ongoing developments, including trade negotiations between the U.S. and the Indian government. “We don’t want significant changes in the commercial environment for generic drugs,” he said.
Although Trump has not announced tariffs on pharmaceutical products, he said he will impose separate tariffs on pharmaceutical companies aimed at bringing manufacturing back to the United States.
In an executive order signed by Trump on Monday, the U.S. aims to cut prescription drug prices by 59% in the U.S., Vohra said the order could be more targeted at brand-name innovative drugs, despite the need to be clearer. He added: “As of now, we understand that this is primarily targeting branded drugs… generic drugs in the United States are already comparable to the rest of the world and in some cases lower.”
Read Also | On the issue of tariffs, has U.S. recognition of key cancer drugs made Cipla stock an attractive buy?
Vohra spoke in a media briefing after the company released its Q4FY25 results on Tuesday.
Cipla’s Q4FY25 revenue rose 9% year-on-year (YOY) to ₹6.73 billion, although the profit after tax was reported ₹$122.2 billion, up 30% from the previous year. The company reports EBITDA ₹15.38 million, profit margin is 22.8%. EBITDA is income before interest, taxes, depreciation and amortization.
During the 25th fiscal year of the year, the company reported revenue ₹275.48 million, up 8% year-on-year, after-tax profit ₹52.73 million, a year-on-year increase of 28%.
An Indian business
Cipla’s One India business grew 8% in the quarter. The company said its branded prescription business continues to outpace the market growth of key chronic therapies.
The company’s North American business reported quarterly revenue of $221 million and historically annual revenue of $934 million, and was backed by the attractiveness of differentiated assets. North America accounts for 29% of the company’s total revenue.
Continue the track
Vohra said the company is committed to continuing its growth momentum, adding that the company has upcoming channels that will drive growth in the U.S.
“While Lenalidomide (Revlimid) will start to drastically reduce over the next two years, the business is now ready to project itself on a different growth trajectory,” Vohra said.
Read this | Data Review: GDP Prediction, Nobel Prize, Cipla’s Dispute
Companies like Cipla will lose their exclusive distribution of lonalidomide (brand Revlimid) at the beginning of next year. “But we think we have a very diverse business model with very significant resilience to offset the decline of Lenalidomide,” Vohra said.
The company’s pipeline includes its peptide products, some of which are expected to be launched in fiscal 26-28.
Industry average
In India, the company focuses on overtaking the Indian Pharmaceutical Market (IPM), fixing drugs, and working with innovators.
“It’s a very important part of the number of patients we are able to bring new science visibility to doctors in India at the doctor level and benefit from these new findings,” Vohra said.
The company is launching GLP-1 products (such as Ozempic or Mounjaro) through partnerships with innovators and their own products.
And this | Home Rift Cloud $700 million for sale Cipla
“I think the biggest opportunity, at least for us, will continue to be the Indian market, and we will launch with other players. We will launch our capabilities through partnerships… We will have our own products and possibly a partnership with another player just to make sure we have full coverage of India’s launch capabilities.”
Semaglutide, a GLP-1 drug known for its brand names Ozempic and Wegovy, will be patented in India early next year.
And Read | Cipla’s Senior Meeting with Two Groups
